iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Cell types differentiated from induced pluripotent stem cells (iPSCs) are frequently arrested in their development program, more closely resembling a fetal rather than an adult phenotype, potentially limiting their utility for downstream clinical applications. The fetal phenotype of iPSC‐derived den...
Egile Nagusiak: | Horton, C, Davies, TJ, Lahiri, P, Sachamitr, P, Fairchild, PJ |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
Wiley
2019
|
Antzeko izenburuak
-
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
nork: Sachamitr, P, et al.
Argitaratua: (2012) -
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
nork: Bravo, M, et al.
Argitaratua: (2021) -
Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset
nork: Sachamitr, P, et al.
Argitaratua: (2018) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
nork: Hanif, Javanmard Khameneh
Argitaratua: (2011) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.
nork: Hanif Javanmard Khameneh
Argitaratua: (2014)